Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for treating CNS disorders

a technology for cns disorders and compositions, applied in the field of compositions and methods for treating cns disorders, can solve the problems that progesterone is not consistently effective in the treatment of the aforementioned syndromes

Inactive Publication Date: 2017-08-17
SAGE THERAPEUTICS
View PDF1 Cites 27 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent is about a specific compound that can be used to treat a certain condition. The text states that the compound has been tested and found to have a beneficial effect in treating the condition. The "therapeutically effective amount" of the compound is the amount that will provide the most benefit in treating the condition. This amount may be the minimum necessary to improve the treatment or reduce symptoms. The term "therapeutically effective amount" can also refer to an amount that works in combination with other treatments to make them more effective.

Problems solved by technology

However, progesterone is not consistently effective in the treatment of the aforementioned syndromes.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treating CNS disorders
  • Compositions and methods for treating CNS disorders
  • Compositions and methods for treating CNS disorders

Examples

Experimental program
Comparison scheme
Effect test

example 1

of 1 and 2

[0258]

[0259]To a solution of A1 (500 mg, 1.29 mmol) in THF (4 mL was added KOH (144 mg, 2.58 mmol) and MeI (200 mg, 1.41 mmol) at 25° C. The mixture was stirred at 25° C. for 2 h. After TLC showed the starting material was consumed, the reaction mixture was treated with water (20 mL) and extracted with EtOAc (30 mL×2). The organic phase was washed with brine (30 mL), dried over anhydrous Na2SO4, concentrated in vacuum. The residue was purified by prep-HPLC to afford (R)-1-((3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(2H-1,2,3-triazol-2-yl)propan-1-one (79.5 mg, 15.4%) and (S)-1-((3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-(2H-1,2,3-triazol-2-yl)propan-1-one (93.1 mg, 18%) as white solid.

[0260]1H NMR (1) (400 MHz, CDCl3) δ 7.67 (s, 2H), 5.27-5.22 (m, 1H), 2.25-2.23 (m, 1H), 2.11-2.05 (m, 1H), 1.87-1.66 (m, 9H), 1.41-1.02 (m, 19H), 0.65 (s, 3H). LCMS Rt=0.9...

example 2

of 3 and 4

[0262]

To a solution of A2 (400 mg, 0.976 mmol) in THF (3 mL) was added KOH (109 mg, 1.95 mmol) and MeI (1.58 g, 11.1 mmol) at 25° C. The mixture was stirred at 25° C. for 2 h. After TLC showed the starting material was consumed, the reaction mixture was treated with water (20 mL) and extracted with ELOAc (30 mL×2), The organic phase was washed with brine (30 mL), dried over anhydrous Na2SO4, concentrated in vacuum. The residue was purified by column chromatography on silica gel (PE / EtOAc=5 / 1 to EtOAc) to afford 1-((S)-1-((3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-1-oxopropan-2-yl)-1H-pyrazole-4-carbonitrile (100 mg, 24.2%) and 1-((R)-1-((3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-1-oxopropan-2-yl)-1H-pyrazole-4-carbonitrile (139 mg, 33.6%) as a white solid.

[0263]1H NMR (3) (400 MHz, CDCl3) δ 7.99 (s, 1H), 7.77 (s, 1H), 5.27-5.25 (m, 1H), 2.73-2.71 (m, 1H), 2...

example 3

of 5

[0265]

[0266]Step 1. Synthesis of A4.

[0267]To a solution of 2,6-di-tert-butyl-4-methylphenol (A3, 24 g, 109 mmol) in toluene (100 mL) was added AlMe3 (2 M in toluene, 27.3 mL, 54.6 mmol) dropwise at 10° C. The mixture was then stirred at 25° C. for 1 hour. To the mixture was added a solution of compound (5R,8R,9R,10S,13S,14S)-13-methyldodecahydro-1H-cyclopenta[a]phenanthrene-3,17(2H,4H)-dione (5 g, 18.2 mmol) in toluene (50 mL) dropwise at −70° C. dropwise under N2. The mixture was stirred at −70° C. for 1 hour. MeMgBr (3 M in ether, 18.2 mL, 54.6 mmol) was added dropwise at −70° C. The mixture was stirred at −70° C. for another 3 hours. TLC showed the reaction was completed. The mixture was poured into citric acid (150 mL, 20% aq.). The mixture was extracted with EtOAc (100 mL*2). The combined organic layer was concentrated under vacuum, purified by column chromatography on silica gel (petroleum ether:EtOAc=50:1 to 1:1) to give (3R,5R,8R,9R,10S,13S,14S)-3-hydroxy-3,13-dimethylte...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
membrane voltageaaaaaaaaaa
timeaaaaaaaaaa
timeaaaaaaaaaa
Login to View More

Abstract

Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein, R1, R2a, R2b, R3 and A are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and / or anesthesia.

Description

RELATED APPLICATIONS[0001]This application claims priority to U.S. Provisional Application No. 62 / 064,957, filed Oct. 16, 2014, the entire contents of which are incorporated herein by reference.BACKGROUND OF THE INVENTION[0002]Brain excitability is defined as the level of arousal of an animal, a continuum that ranges from coma to convulsions, and is regulated by various neurotransmitters. In general, neurotransmitters are responsible for regulating the conductance of ions across neuronal membranes. At rest, the neuronal membrane possesses a potential (or membrane voltage) of approximately −70 mV, the cell interior being negative with respect to the cell exterior. The potential (voltage) is the result of ion (K+, Na+, Cl−, organic anions) balance across the neuronal semipermeable membrane. Neurotransmitters are stored in presynaptic vesicles and are released under the influence of neuronal action potentials. When released into the synaptic cleft, an excitatory chemical transmitter su...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07J43/00A61K9/00A61K31/58
CPCC07J43/003A61K9/0053A61K9/0019A61K31/58A61P25/00C07D249/18C07D231/14C07D295/033C07D249/04C07J13/007C07J75/00C07J9/00
Inventor MARTINEZ BOTELLA, GABRIELSALITURO, FRANCESCO G.ROBICHAUD, ALBERT J.HARRISON, BOYD L.
Owner SAGE THERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com